Single-pill combination of amlodipine and valsartan in the management of hypertension

Bibliography

• Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension 2007;49:69-75
   PubMed Web of Science ®Google Scholar
• Cutler JA, Sorlie PD, Wolz M, et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008;52:818-27
   PubMed Web of Science ®Google Scholar
• Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2002;4:393-404
   PubMedGoogle Scholar
• Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52
   PubMed Web of Science ®Google Scholar
• Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003;163:525-41
   PubMed Web of Science ®Google Scholar
• Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007;115:2761-88
   PubMed Web of Science ®Google Scholar
• Garber AJ, Handelsman Y, Einhorn D, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract 2008;14:933-46
   PubMedGoogle Scholar
• Mancia G, de Backer G, Dominiczak A, et al. 2007 ESH-ESC Guidelines for the management of arterial hypertension. Blood Press 2007;16:135-232
   PubMed Web of Science ®Google Scholar
• Gradman AH, Acevedo C. Evolving strategies for the use of combination therapy in hypertension. Curr Hypertens Rep 2002;4:343-9
   PubMed Web of Science ®Google Scholar
• Ferri C, Croce G, Desideri G. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine. Adv Ther 2008;25:300-20
   PubMed Web of Science ®Google Scholar
• Weir MR. Risk-based classification of hypertension and the role of combination therapy. J Clin Hypertens (Greenwich) 2008;10:4-12
   PubMedGoogle Scholar
• Murdoch D, Heel RC. Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 1991;41:478-505
   PubMed Web of Science ®Google Scholar
• Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997;54:299-311
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Jacob RF, Mason RP. Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease. Am J Hypertens 2008;21:1076-85
   PubMed Web of Science ®Google Scholar
• Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol 2003;23:2155-63
   PubMed Web of Science ®Google Scholar
• Hayashi K, Wakino S, Sugano N, et al. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 2007;100:342-53
   PubMed Web of Science ®Google Scholar
• Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998;97:576-80
   PubMed Web of Science ®Google Scholar
• Tulenko TN, Laury-Kleintop L, Walter MF, Mason RP. Cholesterol, calcium and atherosclerosis: is there a role for calcium channel blockers in atheroprotection? Int J Cardiol 1997;62:S55-66
   PubMedGoogle Scholar
• Mason RP. Atheroprotective effects of long-acting dihydropyridine-type calcium channel blockers: evidence from clinical trials and basic scientific research. Cerebrovasc Dis 2003;16:11-7
   PubMed Web of Science ®Google Scholar
• Eickelberg O, Roth M, Block LH. Effects of amlodipine on gene expression and extracellular matrix formation in human vascular smooth muscle cells and fibroblasts: implications for vascular protection. Int J Cardiol 1997;62:S31-7
   PubMedGoogle Scholar
• Eickelberg O, Roth M, Mussmann R, et al. Calcium channel blockers activate the interleukin-6 gene via the transcription factors NF-IL6 and NF-kappaB in primary human vascular smooth muscle cells. Circulation 1999;99:2276-82
   PubMedGoogle Scholar
• Garcha RS, Sever PS, Hughes AD. Mechanism of action of angiotensin II in human isolated subcutaneous resistance arteries. Br J Pharmacol 2001;134:188-96
   PubMedGoogle Scholar
• Timmermans PB. Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol 1999;15:26F-8F
   PubMedGoogle Scholar
• Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-12
   PubMed Web of Science ®Google Scholar
• Song JC, White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy 2000;20:130-9
   PubMed Web of Science ®Google Scholar
• Thurmann PA. Valsartan: a novel angiotensin type 1 receptor antagonist. Expert Opin Pharmacother 2000;1:337-50
   PubMedGoogle Scholar
• Arun KH, Kaul CL, Ramarao P. AT1 receptors and L-type calcium channels: functional coupling in supersensitivity to angiotensin II in diabetic rats. Cardiovasc Res 2005;65:374-86
   PubMed Web of Science ®Google Scholar
• Hornig B, Landmesser U, Kohler C, et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001;103:799-805
   PubMed Web of Science ®Google Scholar
• Antony I, Lerebours G, Nitenberg A. Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients. Circulation 1996;94:3115-22
   PubMed Web of Science ®Google Scholar
• Ceconi C, Fox KM, Remme WJ, et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007;73:237-46
   PubMed Web of Science ®Google Scholar
• Klingbeil AU, John S, Schneider MP, et al. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003;16:123-8
   PubMed Web of Science ®Google Scholar
• Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996;94:258-65
   PubMed Web of Science ®Google Scholar
• Burnier M, Brunner HR. Comparative antihypertensive effects of angiotensin II receptor antagonists. J Am Soc Nephrol 1999;10:S278-82
   Google Scholar
• Kalinowski L, Matys T, Chabielska E, et al. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 2002;40:521-7
   PubMed Web of Science ®Google Scholar
• Dielis AW, Smid M, Spronk HM, et al. Changes in fibrinolytic activity after angiotensin II receptor blockade in therapy-resistant hypertensive patients. J Thromb Haemost 2007;5:1509-15
   PubMed Web of Science ®Google Scholar
• Seeger H, Lippert C, Wallwiener D, Mueck AO. Valsartan and candesartan can inhibit deteriorating effects of angiotensin II on coronary endothelial function. J Renin Angiotensin Aldosterone Syst 2001;2:141-3
   PubMedGoogle Scholar
• Doumas MN, Douma SN, Petidis KM, et al. Different effects of losartan and moxonidine on endothelial function during sympathetic activation in essential hypertension. J Clin Hypertens (Greenwich) 2004;6:682-9
   PubMedGoogle Scholar
• Nomura S, Shouzu A, Omoto S, et al. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res 2006;117:385-92
   PubMed Web of Science ®Google Scholar
• Dandona P, Kumar V, Aljada A, et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab 2003;88:4496-501
   PubMed Web of Science ®Google Scholar
• Hernandez-Presa MA, Bustos C, Ortego M, et al. ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. Am J Pathol 1998;153:1825-37
   PubMedGoogle Scholar
• Schmeisser A, Soehnlein O, Illmer T, et al. ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression. Biochem Biophys Res Commun 2004;325:532-40
   PubMedGoogle Scholar
• Manabe S, Okura T, Watanabe S, et al. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 2005;46:735-9
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Rifai N, Glynn RJ. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension 2006;48:73-9
   PubMed Web of Science ®Google Scholar
• Sironi L, Gelosa P, Guerrini U, et al. Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall. J Pharmacol Exp Ther 2004;311:989-95
   PubMed Web of Science ®Google Scholar
• Willemsen JM, Westerink JW, Dallinga-Thie GM, et al. Angiotensin II type 1 receptor blockade improves hyperglycemia-induced endothelial dysfunction and reduces proinflammatory cytokine release from leukocytes. J Cardiovasc Pharmacol 2007;49:6-12
   PubMed Web of Science ®Google Scholar
• Yasunari K, Maeda K, Watanabe T, et al. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004;43:2116-23
   PubMed Web of Science ®Google Scholar
• de las Heras N, Aragoncillo P, Maeso R, et al. AT(1) receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits. Hypertension 1999;34:969-75
   PubMedGoogle Scholar
• Li J, Hirose N, Kawamura M, Arai Y. Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits. Atherosclerosis 1999;143:315-26
   PubMedGoogle Scholar
• Haria M, Wagstaff AJ. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995;50:560-86
   PubMed Web of Science ®Google Scholar
• Reid JL, Meredith PA, Donnelly R, Elliott HL. Pharmacokinetics of calcium antagonists. J Cardiovasc Pharmacol 1988;12:S22-6
   PubMed Web of Science ®Google Scholar
• Martin U, Foreman MA, Travis JC, et al. Use of ACE inhibitors and ARBs in hypertensive women of childbearing age. J Clin Pharm Ther 2008;33:507-11
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97
   PubMed Web of Science ®Google Scholar
• Sever P, Dahlof B, Poulter N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006;27:2982-8
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217-25
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75
   PubMed Web of Science ®Google Scholar
• White HD, Aylward PE, Huang Z, et al. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation 2005;112:3391-9
   PubMedGoogle Scholar
• Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-8
   PubMed Web of Science ®Google Scholar
• Douglas JG, Agodoa L. ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial. Kidney Int 2003;63(suppl 83):S74-6
   Google Scholar
• Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31
   PubMed Web of Science ®Google Scholar
• Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363:2049-51
   PubMed Web of Science ®Google Scholar
• Flack JM, Duncan K, Ohmit SE, et al. Influence of albuminuria and glomerular filtration rate on blood pressure response to antihypertensive drug therapy. Vasc Health Risk Manag 2007;3:1029-37
   PubMedGoogle Scholar
• Nasser SA, Lai Z, O'Connor S, et al. Does earlier attainment of blood pressure goal translate into fewer cardiovascular events? Curr Hypertens Rep 2008;10:398-404
   PubMed Web of Science ®Google Scholar
• Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007;29:563-80
   PubMed Web of Science ®Google Scholar
• Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich) 2007;9:355-64
   PubMedGoogle Scholar
• Destro M, Luckow A, Samson M, et al. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS study. J Am Soc Hypertens 2008;2:294-302
   PubMed Web of Science ®Google Scholar
• Poldermans D, Glazes R, Kargiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 2007;29:279-89
   PubMed Web of Science ®Google Scholar
• Flack JM, Calhoun DA, Satlin L, et al. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens 2009;23:479-89
   PubMed Web of Science ®Google Scholar
• Allemann Y, Fraile B, Lambert M, et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. J Clin Hypertens (Greenwich) 2008;10:185-94
   PubMed Web of Science ®Google Scholar
• Sinkiewicz W, Glazer RD, Kavoliuniene A, et al. Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on valsartan monotherapy. Curr Med Res Opin 2009;25:315-24
   PubMed Web of Science ®Google Scholar
• Schrader J, Weisskopf M, Keeling L, Ferber P. The combination of amlodipine/valsartan (5/160 mg) significantly reduces the incidence of peripheral edema versus amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. J Hypertens 2008;26(Suppl 1):S478
   PubMedGoogle Scholar
• Plosker GL, Robinson DM. Amlodipine/Valsartan: fixed-dose combination in hypertension. Drugs 2008;68:373-81
   PubMed Web of Science ®Google Scholar
• Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18:139-85
   PubMed Web of Science ®Google Scholar
• Jamerson K, Bakris GL, Dahlof B, et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press 2007;16:80-6
   PubMed Web of Science ®Google Scholar
• Jamerson KA, Bakris GL, Wun CC, et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens 2004;17:793-801
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28
   PubMed Web of Science ®Google Scholar
• Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992;117:234-42
   PubMed Web of Science ®Google Scholar
• Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999;21:23-33
   PubMed Web of Science ®Google Scholar
• Weber MA. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension. J Hypertens Suppl 1997;15:S31-6
   Google Scholar
• Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995;75:793-5
   PubMed Web of Science ®Google Scholar